← Back to Search

Other

Deprescribing Medications for Physical Function

Phase 4

Recruiting

Research Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 4 months.

Awards & highlights

Study Summary

This trial seeks to better understand how reducing meds with sedative & anticholinergic effects in older adults affects physical function, using lab & real-life tests with wearable & environmental sensors.

Who is the study for?

This trial is for community-dwelling adults aged 65 or older who are currently taking medications with sedative or anticholinergic effects, and have a Drug Burden Index (DBI) score of at least 1. They must agree to a plan that reduces their DBI by at least 0.5. Those with dementia, reliance on walkers for mobility, or unstable medical conditions requiring recent hospital visits cannot participate.Check my eligibility

What is being tested?

The study is testing the impact of reducing medication burden from drugs like antidepressants and opioids on physical function in older adults. Participants will undergo changes to their medication regimen and wear sensors to measure mobility in both lab tests and real-life settings over time.See study design

What are the potential side effects?

While not directly related to side effects of medications, participants may experience withdrawal symptoms or return of original symptoms when reducing these medications as part of the deprescribing process.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 4 months.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 4 months.

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 4 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in gait capacity measured in the lab from baseline to study completion

Secondary outcome measures

Adverse drug events and adverse drug withdrawal events

Change in Digit Symbol Substitution Test from baseline to study completion

Change in Montreal Cognitive Assessment (MoCA) from baseline to study completion

+5 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Deprescribing anticholinergic and sedative medicationsExperimental Treatment1 Intervention

Deprescribing plan targeting a reduction in drug burden index score of ≥ 0.5

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre de recherche du Centre hospitalier universitaire de SherbrookeLead Sponsor

58 Previous Clinical Trials

30,983 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the FDA recognize Deprescribing anticholinergic and sedative medications as a viable therapeutic approach?

"The safety rating for deprescribing anticholinergic and sedative medications is 3, since this Phase 4 trial has been approved."

Answered by AI

How many participants are associated with this clinical research project?

"Affirmative. Clinicaltrials.gov indicates that this medical study, initially posted on March 23rd 2023, is actively recruiting participants. One single medical centre requires 182 people to complete the trial."

Answered by AI

Is enrollment still open for this clinical trial?

"The particulars of this clinical trial, uploaded to the website on March 23rd 2023 and recently amended on September 15th 2023, state that enrolment is still open."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Impact in Older Adults of Reducing Anticholinergic and Sedative Rx Burden on Physical Function Measured by Wearables

Benoit Cossette 2023. "Impact in Older Adults of Reducing Anticholinergic and Sedative Rx Burden on Physical Function Measured by Wearables". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05735379.